Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction (SHINE)
Coronary Atherosclerosis
About this trial
This is an interventional treatment trial for Coronary Atherosclerosis focused on measuring Coronary Disease
Eligibility Criteria
Inclusion Criteria: A person with a diagnosis of acute coronary syndrome who is scheduled to undergo a PCI within 48 hours. A person who is of the legal age of 21, who is mentally competent, and who has signed a written informed consent Exclusion Criteria: A person with known allergy or any contra-indication to active control. A person who has received heparin during more than 48 hours before inclusion in the study. A person treated with warfarin (oral anticoagulant). A person with current bleeding or recognized increased risk of bleeding or history of intracranial hemorrhage. A person who has had a stroke within the last 6 months. A person with uncontrolled hypertension despite antihypertensive therapy. A person with history of clinically significant reduction in blood platelets or neutrophils (white blood cells). A person who has laboratory evidence of significantly reduced renal function or who is dependent on renal dialysis. A person who has a coronary bypass performed during the previous month. A pregnant or nursing woman or a woman of childbearing potential (before menopause) who does not have a negative pregnancy test and does not use a reliable method of birth control. A person who has received any investigational treatment in the preceding month.
Sites / Locations
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis France
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-Aventis
- Sanofi-aventis
- Sanofi-Aventis